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Executive Summary
Congestive heart failure (CHF) is a progressive and debilitating disease that affects millions of people
worldwide. Hundreds of thousands of new cases of CHF are diagnosed each year in the U.S., and this high
volume of patients costs the healthcare industry tens of billions annually. The limited number of donor
hearts and limited long-term effectiveness of pharmacologic treatment necessitate the use of mechanical
circulatory support (MCS) alternatives. Clinical trials of MCS devices have demonstrated that patients
derive substantial survival and quality of life benefits from long-term MCS. Only two total artificial
hearts (TAHs) are approved for clinical implantation in the U.S., and the implementation of TAHs in
the treatment of patients with CHF has increased more than 3 fold in 6 years. These devices and other
new TAHs that are under development, however, have several design limitations and challenges, such as
thromboembolic events, neurologic impairment, risk of infection due to large size, and infection at the
abdominal site of the percutaneous driveline. Additional design limitations include lack of ambulation
due to a sizeable drive console or a heavy portable unit, non-pulsatile blood flow conditions, and the use
of polyurethane membranes and valves which risks rupture or failure after repetitive flexions or openings.
To address these limitations and to provide a new therapeutic solution, we seek to develop an
innovative therapeutic alternative: a unique hybrid-design, continuous flow, implantable, magnetically
levitated TAH (Dragon Heart). The Dragon Heart is designed to support pediatric and adult patients (BSA
> 0.95 sq. meters) with CHF. This TAH has only 2 moving parts - an axial impeller for the pulmonary
circulation and a centrifugal impeller for the systemic circulation. This device utilizes the latest generation
of magnetic bearing technology to levitate the impellers, thus enabling a longer operational lifespan of
15-20 years and larger clearances between the rotating impellers and pump housing. Larger clearances
lead to lower fluid shear stresses, hence mitigating the risk of thrombosis and hemolysis. This design
avoids the use of mechanical or biologic valves and will have an antithrombogenic coating applied to
blood-contacting surfaces, thus further reducing the risk of thrombosis. It will incorporate state-of-the-
art monitoring with Wifi-based sensors to report operational status and will be able to produce both
continuous and pulsatile blood flow. A transcutaneous energy transfer system using wireless technology
will be incorporated to eliminate the percutaneous driveline. The compact Dragon TAH, which has
a target diameter and height of 60 mm by 50 mm, will produce the physiologic pressures and flows
necessary to support CHF patients.
xThis thesis project involved the initial steps in the design and development of the Dragon Heart. The
pump geometries (axial and centrifugal) were established using standard pump design equations and
available literature on similar pumps. Computational modeling using ANSYS CFX 15.0 was performed
to gain insight into the performance of the pump geometries. The axial and centrifugal pump designs
were optimized twice to reduce the outer diameter without compromising pump performance. These
computational models served as the foundation by which prototype manufacturing was completed for
hydraulic testing. Two hydraulic test rigs were constructed to evaluate the performance of the axial
and centrifugal pump prototypes. A blood analog solution of water and glycerin was utilized for the
experiments. The computational studies and prototype testing revealed that the Dragon Heart is capable
of delivering the target blood flows of 1-6.5 L/min and pressure rises of 15-25 mmHg for the pulmonary
circulation and 80-140 mmHg for the systemic circulation at rotational speeds of 2,000-12,000 RPM with
power consumptions of 3-6 watts.
This work successfully reflects the first design phase of the Dragon Heart and represents the foundation
by which to begin Phase II optimization and development. The long-term goal of this research is to
commercialize a novel, less expensive, more compact, low thrombus, and effective therapeutic alternative
for adult and pediatric patients with CHF, thereby saving thousands of lives annually.
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Motivation and Significance
1.1 Introduction
Congestive heart failure (CHF) is a progressive and debilitating disease that affects an estimated 23
million people worldwide.23 In the U.S., approximately 5.1 million people have CHF, and more than
670,000 new cases are diagnosed each year.23–25 The treatment of this volume of patients costs the
healthcare industry almost $35 billion annually.6, 23, 26 In the advanced stages of this disease, treatment
consists of continuous, intravenous, inotropic support and subsequent heart transplantation, when qualifi-
cations are satisfied and a matched donor heart is located.6, 23, 24 In the U.S., in a given year, over 3,000
patients are on the waiting list, but only about 2200 patients are transplanted. More than 15% of those
patients on the donor waiting list will die due primarily to the lack of a sufficient number of donor hearts.
This limitation and the increasing need for biventricular support have necessitated the development of
therapeutic alternatives, such as mechanical circulatory support systems, including total artificial hearts
(TAHs) and ventricular assist devices (VADs).24, 27 The following sections detail the evolution of TAH
designs, TAHs in the development pipeline, and the limitations of these devices, which serve as the
motivation for this thesis project.28
1.2 History and Advances in TAH Technology
1.2.1 History
Since the 1960s, the scientific and medical communities have worked to advance the development
of the artificial heart pumps that are currently saving lives each day. This tremendous momentum and
technological advancement was led by inventors and pioneers, such as Dr. Michael DeBakey, Dr. Willem
Kolff, Dr. William Pierce, and Dr. Yuki Nosé. Four academic enterprises, including the Baylor College of
Medicine, University of Utah, Pennsylvania State University, and Cleveland Clinic, paved the research
and development roadmap for these innovative pulsatile devices during that time, in conjunction with
teamed efforts abroad in Japan, Germany, and other countries.29 After decades of research to optimize the
pump design, durability, biocompatibility, and performance through bench-top and animal experiments,
the Liotta TAH was successfully built as a bridge-to-transplantation (BTT). This TAH was the first device
to be implanted. The recipient was a 47 year old patient who could not be weaned from cardiopulmonary
2bypass support.29 This implantation was successful for 64 hours; however, the patient died of pneumonia
after transplantation. A second human implant occurred in 1981, which was successful in mechanically
supporting the patient for 39 hours.29
In concurrent development, the University of Utah designed the Jarvik Heart.7, 30 The multi-faceted
development approach for this pulsatile TAH design led to the generation of significant in vitro and in vivo
data for the Jarvik-5 and Jarvik-7 designs.31 By the early 1980s, the research team based at the University
of Utah pursued testing of a new TAH called the Utah-100.32 To assess the Utah-100 and its ability to
support life, approximately 183 animal implants were performed on calves and sheep. During these in
vivo experiments, 48 mechanical failures were reported that consisted of 25 severe system failures. As a
result, the design of the Utah-100 was significantly altered to improve geometric shape and to include
more suitable biocompatible materials of construction for the casing and flexing diaphragms. The number
of material layers that comprised the diaphragms was re-specified, along with the amount and type of
lubrication between these layers.33 Similarly, the graft connectors at the inlet and outlet of the TAH were
modified to reduce the propensity for thrombosis formation.
The Jarvik-7 TAH achieved approval for use as a permanent replacement device from the U.S. Food
and Drug Administration (FDA) for a clinical trial.34 Thus, the third human implant was performed by
Dr. William Devries at the University of Utah in which the Jarvik-7 was implanted into Dr. Barney Clark
in December of 1982; he lived for 112 days. Another recipient of the Jarvik-7 was William J. Schroeder
in November 1984.34 He lived for 620 days, much longer than Dr. Clark. One year later, in August
1985, Dr. Jack Copeland at the University of Arizona Medical Center (UAMC) achieved an important
milestone by being the first surgeon to implant the Jarvik 7 as a successful bridge-to-heart transplantation
(BTT).34–37 As of 1991, the Jarvik-7 was no longer clinically available as a TAH in the U.S., and it
underwent additional design optimization and development. The scientific, engineering, and medical
lessons learned, however, during these initial implants were invaluable and served as the foundation from
which researchers have pursued new innovative designs of pulsatile and continuous-flow TAHs and blood
pumps for mechanical circulatory assistance.
1.2.2 Advances in TAH Development and Clinical Use
CardioWest TAH
In the early 1990s, the UAMC took over development of the Jarvik-7, also known as the Symbion J7-
100, and changed its name to the CardioWest TAH. By 2001, SynCardia Systems was formed to advance
3the CardioWest TAH in order to reach clinical use.36 Figure-1.1 illustrates the pulsatile CardioWest TAH.1
SynCardia’s CardioWest 70 mL device is currently the first TAH in the world to receive FDA, Health
Canada, and CE Mark approval for clinical use in Class III/IV patients with end-stage heart failure.38
This TAH has also received CE Mark approval for use of a modified Berlin Heart AG EXCOR R© Mobile
Drive Unit, referred to by SynCardia Systems as the EXCOR TAH-t Driver. The mobile driver affords the
patient increased ambulation and mobility, which are known to enhance recovery and improve strength
and wellness.39 This enhanced mobility was not possible with the previous, large driver unit, referred to
as “Big Blue”, which constrained patients to the hospital bed. This device has two layered polyurethane
ventricular chambers with a capacity of 70 mL, four mechanical valves, two drive lines that are 7 ft in
length and that exit through the upper abdomen and connect the device drivers and battery pack.40 This
TAH has been successfully implanted in over 1,000 patients.41As a therapeutic alternative for smaller
patients, such as women and children, SynCardia developed a reduced volume (i.e. 50 mL) version of
the CardioWest TAH, which received FDA approval in 2013 for BTT and destination therapy (DT) for
patients at risk of imminent death and having a BSA of 1.2-1.79 meters squared.42 In June 2014, the FDA
approved of the clinical use of SynCardia’s new c©Freedom Portable driver for their TAH recipients.
Figure 1.1: CardioWest TAH.1
AbioCor TAH
Similar to the CardioWest TAH, the pulsatile AbioCor TAH was designed to have a fully implantable
configuration with no protrusions through the skin.43 Figure-1.2 displays the AbioCor device and
4system components.2 This TAH , which weighs approximately 1 kg, is made of biocompatible titanium
and polyurethane materials. Integrated within the TAH is a miniature centrifugal pump that utilizes
a pressurized, low viscosity, hydraulic fluid to force deformation of the polyurethane chamber and
eject blood from these chambers. A two position switch valve alternates its position, which releases
the hydraulic fluid and modulates the sac filling pressure, thus generating the left and right cardiac
pressures.44 The valve and hydraulic pumping system alternates at rates of 75-150 positions per minute;
this equates to producing a pulse rate of 75-150 beats per minute. This robust drive system enables the
TAH to deliver cardiac outputs of 4-8 L/min. The TAH is powered using a transcutaneous energy transfer
(TET) system. In the event of device or component failure, an internal battery is located in the abdomen
and allows the device to run for approximately 20 minutes until an external power source is located.
External power sources include a bedside console unit, as well as a portable console unit that can be
carried in a vest, handbag, or on a belt. The bedside unit connects to standard wall sockets and converts
the supplied power to the TET system; it is used in the postoperative setting and when the patient is
at-home with the device. This unit also provides clinicians with an interface to monitor the TAH, make
operational adjustments to it, and evaluate alarm settings. The use of the TET drive system reduces the
risk of postoperative infections and other complications that often result from a tether or drive line exiting
the thorax.44, 45
Figure 1.2: Abicor TAH: A) Device, B) Support system and placement of components.2
On average, the fourteen patients who were implanted with the AbioCor between 2001 and 2004
lived for only five months.44, 46 The longest surviving patient, however, lived for 17 months. During this
time, the most frequently reported adverse events were related to thromboembolic events that occured
due to cell accumulation on the valve struts that are attached to the left atrial cuffs. In 2006, the U.S.
5FDA approved use of the AbioCor TAH under the Humanitarian Use Device (HUD) provision for DT.
Abiomed, however, has since stopped working on further development or improvements of the Abiocor
TAH.
1.3 TAHs Under Development
Currently, the only two TAHs that are approved for clinical use in the U.S. are the CardioWest and
the AbioCor. Several devices are under various stages of development to overcome known limitations of
the pulsatile CardioWest and AbioCor TAHs, such as bulkiness, thrombosis, and durability, to name a
few. The subsequent sections describe the reported progress of the new devices under development per
the literature.
Carmat TAH
European Aerospace and Defense Systems, in partnership with Dr. Alain Carpentier who invented
the Carpentier-Edwards R© heart valves, is currently designing a pulsatile TAH to function as a permanent
solution to heart failure.47, 48 Carmat, after signing an agreement with Edwards Life Sciences, plans to
use the Carpentier-Edwards biological heart valves in its design; this will be the first use of the biological
valves in a blood pump or TAH.48, 49 The Carmat TAH (Figure-1.3) uniquely comprises a prosthetic
design that is part bovine and part machine.3, 47 The TAH consists of two large chambers that are separated
via a bio-membrane. The flexible membrane acts as a divider within each chamber, holding hydraulic fluid
on one side. A pump then forces the fluid into and out of the chambers, causing the membrane to deflect
and displace the blood on the other side of the membrane. The blood-contacting side of the membrane
is made of the pericardial tissue of a cow heart to improve biocompatibility. Incorporation of cardiac
tissue into the bio-prosthetic valves, a set of sensors that measures flow and pressure, and a specialized
control system enables the detection and measurement of the patient’s level of physical activity and make
necessary adjustments to the pressure generation and cardiac output. This TAH is able to deliver 2 to 9
L/min of pulsatile flow with flow adjustment capabilities on the pulmonary side in consideration of the
bronchial shunt.29 The device is further reported to be of cardiac size and has an external power supply
and driver unit. Benchtop experiments revealed low platelet adhesion and minute blood cell deposition
on the membrane surfaces in comparison to controlled cases.29 Low mechanical durability due to using
biological tissue, however, may limit long-term use of the TAH.47 In December 2013, the Carmat TAH
began clinical trials in Europe; the first patient to be supported by this TAH survived for approximately
675 days, and clinical data have not been released.29, 50 The company is preparing to seek FDA approval
by 2016.51
Figure 1.3: Carmat TAH.3
BiVACOR TAH
The BiVACOR is a TAH that utilizes third generation magnetic suspension technology.4, 52, 53 Figure-
1.4 displays the BiVACOR TAH.4 The device, which has an axial length of 70 mm and diameter of 60
mm, can be implanted into smaller patients having a BSA below 1.5 m2. In vivo studies show that it can
provide full support (above 8 L/min) to the systemic and pulmonary circulatory systems under normal,
failing, and absent heart conditions.4 The BiVACOR has a disc-like single rotational component with a
set of uniquely designed blades on the top and bottom. This configuration is basically a double-sided
centrifugal impeller with a single motor driving both impellers at the same rotational speed.53 The rotor
is levitated within the device housing by an active magnetic suspension system.52 Rotation is induced
by an electromagnetically coupled motor. Movement of the impeller within the pump domain inversely
alters LVAD and RVAD outflow.52 The outflow alterations match flow requirements for pulmonary and
systemic circulations, while maintaining adequate atrial filling pressures during in vivo studies.4 The
controller of the BiVACOR utilizes the Frank-Starling law to balance flow by detecting changes in inlet
and outlet pressures. The controller then automatically adjusts the axial positioning of the impeller to
accommodate the changes in order to balance physiological left and right pressures and flow conditions.13
Development and experimental testing of this device is ongoing with calf implants underway showing
low thrombus.
7Figure 1.4: BiVACOR TAH.4
Figure 1.5: Cleveland Clinic CFTAH and Pump Components.5
CFTAH-Cleveland Clinic
The Cleveland Clinic is developing a TAH that functions without mechanical valves or sensors.54
This continuous flow total artificial heart (CFTAH) incorporates second generation drive technology.
Figure-1.5 illustrates the CFTAH.55 This CFTAH extends 6 cm in diameter and 10 cm in length. This
device is similar to the AbioCor in the internal regulation of left and right pump pressures. This TAH
couples a right ventricular assist device (RVAD) and left ventricular assist device (LVAD) into one
unit, utilizing a single drive motor and power cable. Developers are considering an algorithm to apply
oscillating rotational speed impulses to the CFTAH in order to generate pulsatile flow conditions and
are investigating the use of TET technology.54 Durability experiments and continuous load testing of the
batteries used in these applications are being conducted to evaluate the failure rates.56
81.4 Alternatives to the TAH: Biventricular Devices
Another promising method for BTT involves the implantation of two blood pumps or VADs as
biventricular mechanical circulatory support (BiVADs). The following sections detail this combination of
blood pumps used in a BiVAD configuration.
9BiVADS: DuraHeart + Jarvik 2000
In 2001, the Terumo DuraHeart (Figure-1.6) was coupled with the Jarvik-2000 to generate biventric-
ular support for a 34 year old female.57 The BiVAD configuration included the Jarvik-2000 as the RVAD
and the DuraHeart as the LVAD. The Jarvik-2000 (Figure-1.6) is an axial flow VAD that provides 3-6
L/min at physiologic pressures for 8,000-12,000 RPM, weighs approximately 90 grams, and is 2.5 cm in
diameter by 8 cm in length.6, 45, 58 In contrast, the DuraHeart has an external diameter of 7.2 cm and a
height of 4.5 cm.27 It incorporates covalently bonded, heparin coated blood-contacting surfaces. During
mechanical circulatory support, this configuration of devices made it challenging to balance the blood
flow through each of these devices. Nevertheless, the patient was able to survive longer than the average
wait time for a heart transplant and was successfully transplanted. This implantation demonstrated the
strong capabilities of the BiVAD configuration, and thus clinicians have pursued total cardiovascular
support using coupled VADs.58
Figure 1.6: (A) Jarvik 2000 VAD6 and (B) DuraHeart VAD7 Right.
BiVADs: Gyro + Gyro
The Baylor College of Medicine, in collaboration with Miwatec and the New Energy and Industrial
Technology Development Organization (NEDO), has developed blood pumps that can be utilized to form
a BiVAD configuration.13, 59The Gyro PI-601, Gyro PI 700 (Figure-1.7) series and the Gyro C1E3 are
designed as 2nd generation, continuous flow, centrifugal artificial heart pumps.59 The Gyro PI-601 pump
is supported by a double pivot bearing system, has an eccentric inlet port and two vanes, as well as an
outlet port.59 The Gyro 700 series has similar components, but different materials of construction.60
Researchers purport that two of the Gyro pumps can be connected to the native heart, instead of requiring
complete removal, and both function independently.59 For biocompatibility, albumin coated grafts as well
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as a titanium alloy housing and impeller are utilized, which reduces the likelihood of thrombosis.59, 60
In vivo bovine studies supported the two-VAD system in the preperitoneal space, showing no signs of
overlapping or compression.59 Although the Baylor School of Medicine reports that in vivo testing
provided support that the Gyro BiVAD could sustain a patient undergoing exercise, the pumps have a
high risk of ventricular suction and a large surface area that contacts the blood cells. In clinical reports,
infection was a major problem, and thrombus was found at the pivot bearing.60 In addition, researchers
have yet to report on the durability of the pivot bearings and extent of wear over time.59 As an optimization
of the PI-710 series, the NEDO PI-710 also functions as a BiVAD.8 The mechanical circulatory support
system includes unique features, such as the use of TET technology. The NEDO PI-710 is a centrifugal
pump with bearings, but also incorporates a hydraulically-levitated impeller, much like the BiVACOR.
The researchers have also created a combined actuator and controller, which can easily be implanted.
The NEDO PI-710 blood pump is a totally implantable system and resolves many of the complications
experienced with the PI-710 and earlier designs.8
Figure 1.7: Gyro: NEDO PI-710 Ventricular Assist Device.8
BiVADS: CorAide + DexAide
The Cleveland Clinic has also developed the CorAide (LVAD) and DexAide (RVAD) (Figure-1.8) to
be used in conjunction to form a BiVAD system.53 The DexAide was developed similar to the CorAide
pump. Thus, the VADs have a pump design consisting of a centrifugal rotating assembly, a stator
assembly, and a volute housing assembly.13, 61 In addition, both VADs are implantable and utilize third
generation magnetic and hydrodynamic bearings to levitate the rotor.13 The pumps are equipped with a
blood-lubricated fluid film bearing between the suspended rotating assembly and stator assembly that
reduces mechanical contact and flow stasis.61 Each pump is powered by a portable, external, electronic
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driver system. A unique control system has been designed for the two pumps functioning together as a
BiVAD. The systems can be programmed to operate the pump at a fixed speed control or an automatic
physiologic control mode.61 While the CorAide LVAD has begun clinical trials, the DexAide RVAD
has only reached animal studies. For the BiVAD configuration using both VADs, an animal study was
performed at the Cleveland Clinic; the LVAD rotated at a constant 2600 RPM, and the rotational speed
of the RVAD ranged from 2,000-3,200 RPM.61 On the contrary, a second animal study was performed
where the RVAD rotated at 2600 RPM while LVAD speeds were varied. The results of these studies
showed challenges balancing blood flow rates through the pumps. Researchers at the Cleveland Clinic are
optimizing the design of the control algorithm in order to improve operation of the CorAide and DexAide
and to resolve the unbalanced flow issues.61
Figure 1.8: BiVAD Support with DexAide RVAD and CorAide LVAD.9
BiVADs: Jarvik 2000 Flow Maker+ Jarvik 2000 FlowMaker
The biventricular implant of two Jarvik 2000 FlowMakers (Figure-1.9) occurred in 2003 to mechan-
ically support a 21 year old man who was diagnosed with idiopathic dilated cardiomyopathy. After
receiving an initial Jarvik LVAD, the patient developed worsening right heart failure, and a second Jarvik
2000 FlowMaker was implanted as an RVAD. The patient lived for another twelve days on BiVAD
support, but died from sepsis and hepatic failure. The use of these axial flow pumps for biventricular
mechanical support sparked an increased interest in research to address balancing the pulmonary and
systemic blood flows.10, 23, 62 In 2004, Kindo et al.7 investigated a biventricular configuration using two
Jarvik 2000 FlowMakers and specifically explored how to balance the flow rate through each VAD. This
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animal study demonstrated feasibility of using the two VADs in a BiVAD configuration. As a result,
biventricular implants commenced in Europe using the Jarvik FlowMaker.23 A new controller design,
however, might be required for a BiVAD configuration since current controllers allow the patients to
manually adjust the rotational speed of the pump, and a careful balance of the systemic and pulmonary
blood flows is essential to the success of biventricular mechanical circulatory assistance.63
Figure 1.9: Jarvik 2000: Biventricular Support10
BiVADs: HeartWare + HeartWare
Similarly, dual HeartWare VADs have been employed to support patients (Figure-1.10). The Heart-
Ware VAD is a third generation, hydrodynamic centrifugal pump that has a volume of 45 mL. It has a
mass of 45 grams and was designed to deliver 2-10 L/min for 0-170 mmHg over 2,000-4,000 RPM.31 It
was realized that the RVAD pump could not rotate low enough to balance the blood flow conditions. Thus,
developers placed bands on the outflow grafts in order to reasonably balance flow conditions. Banding
of the outflow grafts, however, changes flow patterns at the outlet of the pumps and places a large back
pressure on the rotor; this could lead to instability and irregular flow conditions and promote hemolysis
and thrombosis. To-date, approximately seventeen patients have been implanted with dual Heartware
VADs with a 30-day survival rate of over 80%.
BiVADs: HeartMate II + HeartMate II
Following a study utilizing two Jarvik 2000 Pumps, Frazier et al.30 reported the clinical application
of HeartMate II VADs as a BiVAD in 2009 (Figure-1.11). The HeartMate II was approved in 2010
by the FDA as a permanent treatment for advanced heart failure.6 As of 2012, this VAD is the only
continuous flow LVAD approved by the FDA for BTT and DT. The HeartMate II can be implanted in
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Figure 1.10: HeartWare HVAD: Biventricular Support11
children and adults with a BSA of 1.3 m2 or higher. The pump is contained inside the chest cavity
while drive-lines extend from the chest to the controller and batteries on the external holster. This LVAD
has been implanted in over 10,000 patients, making it one of the most widely used implantable blood
pumps. The smaller size of this device makes it an option for implantation in smaller sized people such as
women.64 As a BiVAD, the HeartMate II-HeartMate II combination performed reasonably well once a
flow balance between the pumps was achieved. It was determined that refinement of the atrial cuffs, and
careful balancing of pulmonary and systemic circulation blood flow is necessary before this dual pump
configuration can be used on a larger scale.12
Figure 1.11: HeartMate II: Biventricular Support12
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BiVADs: Berlin Heart + Berlin Heart
Another successful VAD used for biventricular support is the Berlin Heart. Figure1.12 illustrates a
Berlin Heart pump.13 This VAD was first implemented in the United Kingdom in November 2004.65 The
Berlin Heart EXCOR is offered in multiple sizes with stroke volumes ranging from 10-60 mL. The smaller
pumps have been used in neonates and are approved for use in patients having mass of 3-8 kg. Another
size of device is more appropriate for patient masses of 20-25 kg. The Berlin VAD is an extracorporeal
blood pump. Silicone cannulas connect to the left ventricle and ascending aorta and then connect directly
to the Berlin EXCOR.64 This VAD is electro-pneumatically driven and is the preferred pneumatic VAD
for pediatric applications. While the adolescent pumps utilize trileaflet valves, the VADs intended for
adults use monoleaflet tilting disc valves. All of the VADs are encased in polyurethane chambers and are
most commonly used for left ventricular assistance. As a BiVAD, between January 2006 and February
2012, nine patients were mechanically supported using this combination for total cardiac output. The
30 day survival rate was 75% and support time ranged from 4 - 525 days. In two patients, thrombus
accumulation made it necessary to change the BiVAD combination three times.65
Figure 1.12: Berlin Heart VAD.13
1.5 Clinical Demand, Limitations, and Future Directions
According to the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS)
database, the implant rate for the CardioWest TAH has increased from an average 22 devices per year in
2007 to 66 devices per year in 2013.66 In addition, an improvement in outcomes and survival at 3 and
6 months among patients with biventricular dysfunction supports the use of a TAH when indicated.67
The trends demonstrate a growth in confidence, in use, in success, and in need for patients suffering from
heart failure. Adoption of TAHs for the clinical treatment of patients directly correlates with mechanical,
technological, and physiologic constraints of the pumps that are currently available.
Current TAH designs have reported limitations in usage or potential implementation due to known
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physiologic challenges, such as hemorrhagic stroke, thromboembolic events, neurologic impairment, and
infection due to the bulkiness of the device and bacteria entering the tissue at the percutaneous drive-line
entry site, which may result in local or systemic immune response.27, 29 Some TAH designs could also
limit ambulation by having a large drive console or a heavy portable unit; it is well known that patient
ambulation correlates to better outcomes and overall survival rates. We still do not know whether humans
can tolerate the long term absence of pulsatile blood flow.29 Several studies indicate that long-term
non-pulsatile support is a viable option based on clinical experience with left VADs that act in parallel
with the native systemic ventricle.68–72 However, in a majority of cases, total assistance of the systemic
ventricle is rare, and thus the contracting ventricle forces a portion of the pulse wave through the VAD
during each contraction. Additional data regarding the viability of long-term complete continuous-flow
conditions would be beneficial as new TAHs and BiVAD configurations are developed and implemented,
respectively.29 Likewise, mechanical and technological limitations of the current state-of-the-art include
a risk of membrane rupture and valve failure in pulsatile devices, higher power consumption as compared
to VADs, and patient size constraints due to device bulkiness.
Emerging technology will advance the state-of-the-art in TAH and VAD development and address
design limitations for a wider range of patients - from infants to adults and males to females. New
anticoagulation schemes could be devised for those devices with inherently lower risk of hemolysis and
thrombosis. The utilization of new materials of construction will ensure that the drive consoles and
wearable adjunctive components are lighter, safer, more portable, and use options for a wider population
of patients. To address driveline and power consumption issues, the implementation of new TET power
systems based on wireless technology, a coplanar inductive coupling energy system, or high efficiency
resonant coupling unit using magnetic fields is possible.73, 74 Additional solutions include new designs
that achieve the same performance in a smaller and more compact size, and thus could be employed
to mechanically support a wider patient population. The unique coupling of continuous-flow blood
pumps with only 1 or 2 moving parts, rather than a pulsatile configuration, avoids the use of valves and
membranes that could rupture or fail. Superior biomaterials, biologic tissue valves, and coatings with
drug eluting properties could be incorporated into blood contacting surfaces to lower risks of hemorrhagic
stroke and thromboembolic events. In addition, the monitoring of TAH devices can be significantly
improved through telemedicine with implanted external sensors using WiFi to report motor currents,
flow rates (if a flow rate sensor is used), magnetic bearing currents, and impeller positions (if a sensor
is used such as in a magnetically suspended system). Incorporation of such innovative features in the
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next generation of devices will improve patient outcomes and the clinical management of patients with
end-stage CHF. While this field has already achieved pioneering and significant milestones, opportunities
for advancement are boundless. Continued advances in the design and development of TAHs could take
patient care to levels previously unexpected and result in saving thousands of lives annually.
1.6 The Dragon Heart
At Drexel University, the BioCirc Lab in the School of Biomedical Engineering, Science and Health
Systems is working to advance the state-of-the-art in TAH design and to address known limitations in these
medical devices as previously discussed. Table-1.1 identifies current limitations of existing technologies
and indicates how the Dragon Heart will address these limitations through design advancement.
The Dragon Heart occupies the space of a single VAD and implements a magnetic suspension-motor
drive system. The more compact size of this device has less foreign surface and therefore reduces a risk of
infection and an immune response. The use of magnetic bearings, as opposed to conventional mechanical
or pivot bearings, exhibits larger clearances (5 x larger) between rotating and stationary surfaces. The
axial RVAD and centrifugal LVAD will have an antithrombogenic coating applied to all blood-contacting
surfaces, reducing the risk of thrombosis. The Dragon Heart will incorporate wireless technologies to
make this device completely intracorporeal, removing the risk of infections from percutaneous power
and drive lines exiting through the abdomen. With the use of a TET system, power will be supplied
to the internal components without breaking the skin. A WiFi or Bluetooth system will be applied to
provide control signals and report operational statuses to and from the TAH. The Dragon Heart will be
strategically designed with lighter materials, reducing the weight of components such as the batteries
and controllers. This TAH, with an overall size of 60 mm x 50 mm, will produce the pressures and flows
necessary for CHF patients. The design will generate 3-6 L/min of flow with a pressure of 15-25 mmHg
for the pulmonary circulation and 80-140 mmHg for the systemic circulation at speeds of 2,000-15,000
RPM. By ramping speed, the Dragon Heart has the capability to provide both pulsatile and continuous
flow support without the use of valves or membranes. Figure-1.13 Illustrates the design of the Dragon
Heart. This thesis details the initial steps in the development of the Dragon Heart and represents Phase-I
of the development process for this new and innovative medical device.
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Table 1.1: Limitations of Current Devices Addressed By The Dragon Heart
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Figure 1.13: Dragon Heart TAH; A. Implant Configuration; B. Centrifugal LVAD Component; C.
Axial RVAD Component; D. Dimensions and Flow Patterns
19
2
Project Objectives
The purpose of this project is to design and advance the development of a hybrid TAH. The long-term
goal is to commercialize a novel, more compact, biocompatible, energy efficient, and effective therapeutic
alternative for smaller patients with congenital heart failure. After development and clinical testing, the
Dragon Heart will be the smallest and safest TAH on the market, thus bringing more life saving options
to adults and pediatric patients (BSAs > .95 m2) in need of total cardiac support. In support of this goal,
this thesis project designed, prototyped, and carried out a Phase I development of the Dragon Heart
utilizing bench top and computational analyses. The following specific aims were accomplished during
this project:
1. Establish a hybrid, combined axial and centrifugal blood pump that could function as a TAH and
that could incorporate the latest generation magnetic suspension technology.
2. Develop a test-rig and computational framework to support performance evaluation of the TAH
designs.
3. Demonstrate the abilities of the hybrid TAH to achieve target design specifications through compu-
tational studies and prototype testing.
This research represents the first steps toward designing a TAH, for destination therapy or BTT. This
new medical device (Figure-1.13) will address the limitations of current TAHs and be a novel therapeutic
alternative for adults and pediatric patients suffering from end-stage CHF.
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Materials and Methods
3.1 Conceptual Design
After several discussions and brainstorming sessions, the BioCirc Lab chose to pursue the design
that places the axial impeller inside of the central spindle hub of a centrifugal VAD. In conventional
centrifugal VADs, this central spindle or hub space is void or contains bearings to counteract radial or
axial loads on the impeller. We chose this configuration to make better use of this space. It also enabled
the design to be as compact as possible. We were unsure as to whether the general space was large enough
to accommodate motors in order to rotate the axial and centrifugal impellers. Thus, we met with Rotor
Bearing Solutions International, LLC to discuss the feasibility of motor and bearing positioning into our
proposed model. Once confirmation of feasibility was obtained we pursued an invention disclosure and
provisional patent submission.
From here we moved forward with the axial and centrifugal designs, including impellers and the
geometry of adjunctive components. Applying basic knowledge of fluid dynamics, pump design, and
prior experience, the pump geometries were drafted in SolidWorks and discussed with Rotor Bearing
Solutions for confirmation of design capability and manufacturability.
3.1.1 Right Side of TAH (Axial Pump)
The target of the axial pump is to support the pulmonary circulation and generate 3-6 L/min of flow
with a pressure rise range of 15-25 mmHg. The axial pump consists of an impeller, an inducer, a diffuser,
and a straightener, which can be viewed in Figure-3.6. The impeller has 3 helically wrapped blades
around the rotor surface and spins to impart rotational kinetic energy to the fluid. The inducer is intended
to eliminate any pre-rotation in the fluid entering the impeller. The diffuser blades are designed to redirect
the velocity of the fluid leaving the impeller and convert that energy into pressure, which drives blood
flow through the circulatory system. The straightener allows the fluid to exit the pump with reduced
vorticity, thus lowering shear levels and risk of blood cell damage. Figure-3.2 shows 3-D models of the
inducer, diffuser, and flow straightener.
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Figure 3.1: SolidWorks rendering of Axial Impeller
Figure 3.2: Axial Pump Components: A) Diffuser; B) Inducer; C) Flow Straightener
The inducer consists of 4 blades which extend 1.06 cm in front of the impeller. These blades
are rounded on their leading edge to allow a smooth transition of flow around them. Each blade is
approximately .25 cm in width and .32 cm in height. The blades are evenly spaced around the inner
diameter of the pump housing which is .94 cm in diameter across the entire inducer (Figure-3.3).
The diffuser consists of 4 helical blades which are oriented in a reverse direction to the blades on the
impeller. This reverse direction facilitates the decrease in velocity of the fluid, thus accomplishing an
increase in pressure. These blades curve from being 1 cm apart on their trailing edge to being .6 cm apart
on their leading edge. The diffuser extends 1.04 cm behind the impeller and decreases in diameter from
1.41 cm to 1.07 cm (Figure-3.4).
The flow straightener consists of 3 blades which are approximately 1 cm in width and .18 cm in
height. These three blades are evenly spaced around the inner surface of the pump which ranges from .88
cm to 1.13 cm, with an exiting diameter of 1.10 cm. The flow straightener extends .93 cm behind the
diffuser region (Figure-3.5).
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Figure 3.3: Drawing of Inducer
Figure 3.4: Drawing of Diffuser
Figure 3.5: Drawing of Flow Straightener
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Figure 3.6: Conceptual Design of The Axial RVAD
3.1.2 Left Side of TAH (Centrifugal Pump)
The target design of the centrifugal pump is to support the systemic circulation and generate 3-6
L/min of flow with a pressure of 80-140 mmHg. The centrifugal pump ( Figure-3.7) consists of an inlet
volute, exit volute, and an impeller. The inlet volute allows flow to enter the pump and distributes the flow
evenly into the impeller. As shown in Figure-3.8, the bottom volute supports the impeller and directs the
flow out of the pump. The purpose of the exit volute is to collect the flow leaving the impeller and slowly
increase the cross-sectional area such that fluid velocity is converted to pressure at the outlet of the pump.
Figure-3.9 shows the impeller which imparts energy to the blood.
3.2 Computational Modeling
3.2.1 Axial and Centrifugal Pumps
ANSYS Incorporated’s software was used to simulate flow through the TAH pumps. CFX-Mesh was
utilized to generate the mesh for the computational simulations. Two 2.14 million element tetrahedral
finite element meshes were generated for the centrifugal and axial pumps. The mesh was refined by
increasing the number of elements until the values calculated had minimal variance, this is also known
as obtaining grid independence. The CFD solver was set to achieve convergence once the residual error
dropped below 1 x 10-3.The computational pump models, including all flow domains (inlet regions,
inducer, diffuser, volutes, etc.) were imported into the ANSYS-CFX solver to complete the simulations.
Flow through the pumps was set to be steady, and the no-slip condition was applied to all stationary
surfaces. A fluid viscosity of 0.0035 kg/m*s coupled with a fluid density of 1,050 kg/m3 was used to
define the fluid properties for the simulations. The outlet of both pumps was specified as a constant
physiologic and static pressure, and the inlet of the pumps was defined to have an incoming mass flow
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Figure 3.7: SolidWorks Mock-up of Centrifugal Pump For Performance Testing
Figure 3.8: Isometric and Top View of Centrifugal Pump Design
rate for each operating point. The impellers were placed in a rotating reference frame and because of
their orientation, were set to rotate in a counter-clockwise direction. In the rotating reference frames,
the impeller shrouds were defined as a counter-rotating wall (i.e. clockwise). For the axial RVAD, the
inducer, diffuser, and flow straightener were set to be in the stationary reference frame; thus, the rotor hub
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Figure 3.9: Centrifugal LVAD Impeller Design
surfaces were defined as spinning. Similarly, for the centrifugal LVAD, the inlet and outlet volutes were
set to be stationary.
3.3 Hydraulic Test-Rig
The computational modeling and analysis facilitated the determination of an initial design of the
axial RVAD and centrifugal LVAD, and enabed the performance predictions for both pumps. The CFD
predictions demonstrated acceptable performance levels for the RVAD and LVAD (discussed in Chapter-
4). Thus, we sought to perform prototype testing of these designs and constructed two separate hydraulic
test loops for each of the VADs. The hydraulic test-rigs were designed to allow the pumps to circulate a
blood analog fluid in a closed loop system. This fluid is a mixture of water-glycerin that is calibrated
to have a similar density and viscosity as blood. These hydraulic systems enabled measurement of the
pressures and flows generated by the pumps.
3.3.1 Axial Rig
The axial test-rig was designed to have two tanks in line with one another. Having the tanks in line
allowed for hydraulic fluid to be driven from one and into the other by the axial pump. Figure-3.10 shows
the experimental setup for the testing of the axial pumps. The pressure transducer measures pressures
from both tanks allowing for the pressure generation of the pump to be determined. The flow probe uses
ultrasonic technology to record the flow rate in the connecting hose between the two tanks. With this axial
configuration many different axial pump designs can be tested. Additional details about the instruments
and equipment are found below.
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3.3.2 Centrifugal Rig
The centrifugal test-rig was designed to have two tanks, similar to the axial test-rig. However, these
tanks were positioned perpendicular to each other. Centrifugal pumps function by drawing in fluid into
the inlet or top volute of the impeller and utilizing tangential forces, generated by the impeller, to pump
the fluid out in a perpendicular direction. Figure-3.11 shows the experimental setup for the testing of
the centrifugal pumps. Similar to the axial pump test-rig, the pressure transducer collects the pressure
differential between the two tanks and the flow sensor collects the flow rate from the hose connecting the
two tanks together. Additional details about the instruments and equipment are found below; both the
centrifugal and axial pump test-rigs utilized the same basic instrumentation.
Figure 3.10: Experimental Test-Rig (Axial): a) Axial Pump Location; b) Inlet Tank; c) Outlet
Tank; d) Pressure Transducer; e) Resistance Clamp; f) Ultrasonic Flow Probe; g) Ultrasonic Flow
Meter; h) Pressure Transducer Signal Conditioner; i) Oscilloscope; j) Motor; k) Motor Power
Supply and Controller; l) Data Acquisition System.
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Figure 3.11: Experimental Test-Rig(Centrifugal): a) Inlet Tank; b)Outlet Tank; c) Pressure Trans-
ducer; d) Ultrasonic Flow Probe; e) Centrifugal Pump Location; f) Resistance Clamp; g) Data
Acquisition System; h) Motor Controller; i) Motor; j)Motor Power Supply; k) Ultrasonic Flow
Meter; l) Pressure Transducer Signal Conditioner; m) Oscilloscope.
3.4 Error Analysis
In order to calculate the percent error between the computational and experimental results the pressure
and flow coefficients were determined. Equations-3.1 and 3.2 were used to calculate the flow and
pressure coefficients: ϕ represents the flow coefficient, Ψ is the pressure coefficient, ρ signifies the density
of the fluid in kilograms per cubic meter, R represents the impellers radius in millimeters, N indicates
the rotational speed in revolutions per minute, Q is the flow rate in liters per minute, ∆P represents the
pressure rise across the pump in millimeters of mercury, Cϕ is a flow factor constant which is equal to
1.2157 * 1010, and CΨ is a pressure factor constant which is equal to 1.5915 * 105.75
ϕ = Cϕ
Q
NR3
(3.1)
Ψ = CΨ
∆P
ρN2R2
(3.2)
Once these two coefficients were determined for the experimental and computational results for
a specific speed, they were plotted and fit with a trend line to establish an equation for the respected
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data group. ϕcomputational was plotted against Ψcomputational and ϕexperimental was plotted against
Ψexperimental in order to capture the data trends using the regression line. Once these equations were
established, a consistent range for ϕ was chosen to best fit the data across both the experimental and
computational results and was input into the respected equations to formulate new, more consistent values
for Ψ. The percent error was then calculated utilizing Equation-3.3.
%Error =
Ψexperimental −Ψcomputational
Ψcomputational
∗ 100 (3.3)
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3.4.1 Instrument Calibration
Flow Probe Calibration
For these experiments the flow rate of the fluid was recorded using a Transonic Systems Inc. 16PXL
Flow Probe (Figure-3.12). This sensor was used in conjunction with a Transonic Systems Inc TS410
Tubing Flow Module (Figure-3.13). These flow sensors were chosen for their ability to provide accurate
flow data without coming into contact with the fluid inside of the tubing or disturbing the flow in the
test loop. The flow meter was previously calibrated to read the velocity of a 60%Water-40%Glycerin
solution. This flow probe determines the velocity of the fluid via ultrasonic waves and therefore requires
the density of the fluids being tested.
Figure 3.12: Transonic Systems Inc. 16PXL Flow Probe14
Figure 3.13: Transonic Systems Inc TS410 Tubing Flow Module15
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In order to generate a flow-voltage equation for the data acquisition system and the flow probe, the
following steps were performed:
1. A piece of clear tubing was run through the 16PXL Flow Probe.
2. The tubing being run through the Flow Probe was attached to a constant fluid flow source.
3. The Flow Probe was connected to the TS410 Flow Module.
4. The voltage output from the back of the Flow Module was fed into a LabJack U12 DAQ board.(Figure-
3.10)
5. The signal from the U12 DAQ board was then fed into a desktop computer and translated through
LJstream software. This software records the data that is fed from the U12 DAQ board and
translates it through calibration equations.
6. A maximal flow rate through the tubing was set (approximately 7 L/min).
7. For each iteration the flow through the tubing was decreased by .2 L/min utilizing a resistance
clamp on the outside of the tubing.(Figure-3.10)
8. The flow rate was read from the Flow Module and recorded for each iteration.
9. The LJstream software recorded the voltage output from the FlowModule for each iteration.
10. Data was recorded until the flow rate reached 0 L/min.
11. This process was repeated 3 times and an average of the data sets was used to determine the
flow-voltage equation for use in the data acquisition system.
Pressure Sensor Calibration
For these experiments the pressure of the fluid was recorded using a Validyne DP15 Variable
Reluctance Pressure Sensor (Figure-3.14). This sensor was used in conjunction with a Validyne CD23
Carrier Demodulator with LED Display (Figure-3.15). These pressure sensors were chosen for their
ability to provide differential pressure data between the inlet and outlet tank on the test-rig. (Figure-3.10)
This allows for the static pressure at the inlet and outlet of the pump to be recorded. The Pressure Sensor
and Carrier Demodulator are previously factory calibrated. The Pressure Sensor reads the pressure of the
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fluid via flexible membranes located inside of the sensor. Care was taken to ensure that all air bubbles
were removed from the loop and transducer tubing, thus limiting distortion of readings.
Figure 3.14: Validyne DP15 Variable Reluctance Pressure Sensor16
Figure 3.15: Validyne CD23 Carrier Demodulator with LED Display17
In order to calibrate the pressure sensor and demodulator the following steps were performed:
1. Two pieces of clear tubing were attached to the Pressure sensor and to each of the two water
columns shown in Figure-3.16.
2. The Pressure Sensor was connected to the CD23 Demodulator.
3. The voltage output from the back of the Demodulator was fed into a LabJack U12 DAQ board.(Figure-
3.10)
4. The signal from the U12 DAQ board was then fed into a desktop computer and translated through
LJstream software. This software records the data that is fed from the U12 DAQ board and
translates it through calibration equations.
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Figure 3.16: SolidWorks rendering of manometer calibration stand used to calibrate the pressure
sensor that was utilized in these experiments.
5. The right water column was filled to 10 in and the left water column was filled to 45 in.
6. The pressure tranducer was bled to remove air bubbles from both sides of the membrane, fluid was
bled until no air bubbles were visible in the tubing.
7. For each iteration the height of the fluid in the left column was decreased by 1” utilizing a valve at
the bottom of the water column.
8. The height of water was read from the manometer and recorded for each iteration.
9. The LJstream software recorded the voltage output from the demodulator for each iteration.
10. Data was recorded until the water column height differential reached 0 in (both columns were at
ten inches).
11. This process was repeated 3 times and an average of the data sets was used to determine the
pressure-voltage equation for use in the data acquisition system.
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The following equations were used to calculate the pressure difference based on the height of the water
columns :
1inH2O = 1.868mmHg (3.4)
H2ODifferentialHeight = LHeight−RHeight (3.5)
PressureDifferential = H2ODifferentialHeight ∗ 1.868mmHg (3.6)
Hydraulic Fluid Calibration
A blood analog fluid was circulated through the test-rigs. For these experiments the viscosity of the
fluid was calculated using a hydrometer (Figure-3.17) and a Cannon-Fenske viscometer (Figure-3.18).
The solution generated was approximately 40% glycerin and 60% water; it was calibrated to have a
viscosity within the parameters of human blood. The hydrometer and viscometer are previously factory
calibrated. The viscometer is hand blown glass, therefore equations for the viscometer are provided per
its unique geometry.
Figure 3.17: Hydrometer used to calculate the specific gravity of the fluid.18
In order to calibrate the fluid the following steps were performed:
1. Volumes of approximately 40% glycerin and 60% water were mixed together.
2. In a graduated cylinder the hydrometer was floated.
3. The level where the hydrometer met the water surface was collected.
4. The Cannon-Fensk viscometer was then filled with the fluid so that the level was just above the
second line show in Figure-3.18 and placed into a ring stand so that it was upright.
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Figure 3.18: Cannon-Fenske Viscometer used to calculate the viscosity of the fluid.19
5. A timer was started once the fluid level became flush with the first line (the line between the two
smaller bulbs).
6. The timer was stopped when the level of the fluid dropped below the second line shown on the
viscometer.
7. The time it took the fluid to pass between the two markings was recorded.
8. This was repeated in groups of five, four separate times throughout the experiments to ensure
accuracy.
The level of the hydrometer represents the specific gravity of the fluid. The following equation shows
that relationship:
1density(g/cc) = 1specificgravity (3.7)
The equation provided with the viscometer includes constants specific to only that viscometer. The
following equation utilizes these constants and calculates dynamic viscosity:
DynV is(cP ) = 0.003952(mm2/s2) ∗Density(g/cc) ∗DrainT ime(m) ∗ 60(s) (3.8)
Following the construction of the test-rigs, instrument calibration, and determination of an appropriate
blood analog solution, the left-sided centrifugal pump and right-sided axial pump designs were advanced
toward prototype manufacturing and Phase I testing.
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3.5 Prototype Manufacturing
In order to analyze the performance of both the axial and centrifugal pumps they were prototyped in
SolidWorks (Figure-3.20 and Figure-3.19 for the impeller dimensions) and manufactured through a rapid
prototyping process. The impellers were designed so that the blades would spin in a counter-clockwise
direction, which was also considered for the wiring of the motor and threading of the shafts. The 3-D
printing process utilized Somos R©WaterShed XC 11122. This water resistant resin behaves similarly to
acrylonitrile butadiene styrene (ABS) or polybutylene terephthalate (PBT) and yields smooth surfaces.
By using this material, stereo-lithography technology, and the services of Applied Rapid Technology
we were able to produce prototypes within tolerances of 1/1000 of an inch and having the durability to
sustain all of the testing conducted.
Post rapid prototyping, the impellers were taken to the Drexel University Machine Shop and threaded
for fit to the drive shaft. The prototypes were placed on lathes in order to accomplish perfectly centered
shaft positions. The pump housing or casings were sealed using o-rings and silicone sealant and secured
utilizing screws and bolts in preparation for testing. The centrifugal bottom volute (Figure-3.7) was fitted
with an oil seal to prevent fluid from leaking out where the shaft passes through to the impeller.
To support the pumps in the test-rigs (Figure-3.10 and Figure-3.11) shafts were produced utilizing
316 Stainless Steel to prevent rusting or corrosion. Five millimeter stock extrusions were purchased to
match the 5 mm shaft used. These shafts were cut to lengths to fit the different pumps being tested and
machined to have female and male ends. The shaft for the centrifugal impeller was threaded with a M5 x
.8 thread to utilize the full size of the shaft. The centrifugal impeller requires more torque for rotation and
therefore required a larger thread to reduce the likelihood of the shaft stripping the threads on the impeller.
The shaft for the axial impeller was threaded utilizing a M3 x .5 thread to fit the current thread size of
the test-rig. The smaller impeller requires a negligible amount of torque and therefore does not require a
robust thread. By utilizing a smaller thread on the axial impeller, an axially and radially centered location
of the impeller was accomplished. These shafts were screwed into the impellers and individually fitted to
the two different test-rig configurations.
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Figure 3.19: SolidWorks drawing of Axial Impeller
Figure 3.20: SolidWorks drawing of Centrifugal Impeller
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3.6 Experimental Setup and Testing
3.6.1 Axial Pump (RVAD)
The axial pump was placed into the axial test-trig and sealed in place utilizing silicone sealant.
Silicone sealant was used for its ability to generate fluid tight seals. The sealant was left overnight to cure.
The next day the system was flushed and cleaned with deionized water. The proper mixture of glycerin
and water was mixed together to simulate the fluid properties of blood (Section- 5.1 ) and the system was
filled. The valves on the top of the inlet and outlet tanks were opened during filling to allow for the the air
in the system to exit. The pump was run at low speeds to move any trapped air into the two tanks to bleed
out. Due to the compressibility of air in comparison to water or glycerin, any air in the system would
likely lead to inaccurate pressure sensor readings.
The motor was slowly turned on and the speed was increased using a potentiometer. The hall sensor
reading from the motor was read with an oscilloscope and the speed was matched to the desired RPM.
Equation-3.9 was utilized to convert the hall sensor frequency to RPM.
FrequencyInHertz ∗ 60 = SpeedInRPM (3.9)
Once the desired speed was accomplished, the hose clamp shown in Figure-3.10 was tightened until
the fluid flow was at 1 L/min. Data was collected after each hose clamp adjustment or interval. The
hose clamp was loosened allowing the flow to increase by .1 L/min each interval until the flow maxed
or reached 5 L/min. This collection of data included over 10,000 pressure and flow readings for each
interval. This process was repeated for all of the desired speeds. The results of this testing can be seen in
Figure-5.8.
3.6.2 Centrifugal Pump (LVAD)
The centrifugal pump was placed into the centrifugal test-trig and sealed in place utilizing silicone
sealant. The silicone was used on the inlet of the pump and, similarly to the axial pump, was left overnight
to cure. The outlet of the pump was attached to the outlet tank via hose clamps and tubing. Before testing
of the pump, the sealed system was flushed and cleaned utilizing deionized water. The proper mixture of
glycerin and water was produced to simulate the fluidic properties of blood (Section- 5.1) and the system
was filled. The bleed valves on both the inlet and outlet tanks were opened and the system was filled.
The tubing was maneuvered and the pump was spun by hand to move any air bubbles to the two tanks.
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Because of the orientation of the testing of the centrifugal pump, the pump had to be spun up to 2k RPM
several times to work all of the air out of it. The pump was spun up and stopped and the air was bled off.
This was repeated until no air was present in the pump.
The motor was slowly turned on and the speed was increased using a potentiometer. The hall sensor
reading from the motor was read with an oscilloscope and the speed was matched to the desired RPM.
Equation-3.9 was utilized to convert the hall sensor frequency to RPM.
3.6.3 Flow Design and Construction
The flow system was designed to be able to test both centrifugal and axial pumps (Figure-3.11 and
Figure-3.10). The major difference in these configurations was the position of the outlet tank. The
axial pump required the outlet and inlet tanks to be perfectly in line for the flow to pass straight through.
However, centrifugal pumps bring fluid in one direction and, using radial force and centrifugal motion,
displace the fluid in a perpendicular direction. Therefore, the test-rig had to be able to be reconfigured
with the tanks in line as-well-as perpendicular to one another. The base plate which the tanks and motor
mount to was designed with mounting holes that could accommodate both of these orientations.
The motor, shaft, and bearing system was mounted to the base plate in a fixed position. To allow
the impeller position inside of the VADs to be adjusted allowing proper alignment and maintenance of
proper clearances inside of the pumps, the motor, bearing housing, and main shaft were mounted on a
micrometer. The micrometer was then mounted to a slide rail with an adjusting knob. This rail utilized a
large threaded rod to allow for large adjustments to the impeller position. With this configuration, large
and precise adjustments could be made to the position of the impellers inside of the pump housings.
The shaft was designed so that it could handle the torque of centrifugal and axial impellers in the
range that we would be testing. A 5 mm shaft was determined to be the largest shaft that could be used
for the axial impellers we would be modeling and testing; any larger shaft would interfere with the sizes
of the impellers. In order to prevent any deformation of the 5 mm shaft that might be caused by the
high speeds and loads it would be subject to, the shaft was tapered down to only have a section of it
measuring 5 mm in diameter. This supplied more support to the shaft itself and reduced the likelihood
of any deformation in the shaft. 316 stainless steel was used on the shaft for its structural and corrosion
resistant qualities. By utilizing structural steel, bearings, bushings, and other supports, the shaft was
capable of supporting the torque supplied by any centrifugal impeller we would be testing. The shaft was
mounted in a bearing block which horizontally positioned the shaft to go through the center of the outlet
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tank. Two bearings were used approximately 3 in apart to stabilize the axial position of the shaft and
prevent any whip that might occur at the impeller location of the shaft. The shaft extended from the back
side of the bearing block and attached to the motor via a spider coupling.
The motor used was a Faulhaber Brushless DC-Servomotor. Series 4490 H 024 BS was chosen for its
speed and torque ratings. With a stall torque of 197.8 mNm and a max speed of 16,000 RPM this motor
allowed us to have enough torque to spin up both centrifugal impellers and axial impellers within our
specified ranges. In designing the impellers the motor simply constrained the design by Equation-3.10.
With the use of bearings and bushings the coefficient of friction was assumed to approach a value of 1.
The mass of the impellers was approximated using SolidWorks. From the Tools menu, mass properties
were selected giving data similar to what is shown in Figure-3.21. By converting the mass to kg and
applying the mass of the impeller to Equation-3.10, the torque was solved for and determined to be
below the motor’s stall torque.
u = coefficient of friction; m = mass; a = acceleration; r = radius of impeller
T = u ∗m ∗ a ∗ r (3.10)
Figure 3.21: SolidWorks>Tools>Mass Properties
In the axial configuration, the shaft was covered with a sleeve (Figure-3.22) that remained stationary
while the shaft spun inside of it, preventing disturbance of the fluid in the outlet tank caused by the contact
of the shaft with the test fluid. The sleeve was designed to mount to the outlet tank and remain stationary.
The impeller shaft could then pass through this sleeve, protruding out the front, only allowing for minimal
contact of the shaft with the fluid. To prevent fluid from back washing through the sleeve, a bushing and
oil seal were utilized. A bushing was used where the 5 mm shaft protruded from the sleeve. This bushing
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not only acted as an initial barrier to keep fluid from passing into the sleeve, but also provided additional
stabilization of the shaft. The oil seal was placed at the back of the sleeve and prevented any fluid flow
from passing between the shaft and its sleeve. The outside of the shaft sleeve was designed to allow the
fluid to pass over in a streamline fashion. This sleeve also preemptively acts to reduce hemolysis that may
occur during testing utilizing bovine blood. An exposed metal shaft during blood studies would result in
increased damage to blood cells due to elevated shear levels. There was no need for a sleeve on the shaft
that would spin the centrifugal impeller given it did not pass through either of the tanks or any fluid path.
Figure 3.22: Shaft Sleeve: Axial Configuration
The filling of both test-rigs occurred in a similar fashion: the pumps would push the fluid into the
outlet tank, through a hose and flow sensor, into the inlet tank, and finally back into the pump. Both
fluid setups had a differential pressure sensor placed between the inlet and outlet tanks which allowed for
the pressure increase caused by the impeller to be recorded. By collecting the pressure in the inlet tank
and outlet tank at the same time, subtracting the values, and taking the absolute value, the characteristic
pressure rise of each pump was collected and calculated.
A data acquisition system was designed to control the motor and temperature and to collect all of
the desired data. The pressure and flow data was sent into a signal conditioning data acquisition module
and fed to a desktop computer for processing. The motor was controlled by wiring it to a compatible
motor controller and adding an adjustable potentiometer to set specific speeds. The motor controller was
powered with multiple power sources, as needed for different desired torques.
Additionally, temperature control was taken into account for the design of this multipurpose test-rig.
In future studies, if blood was to be tested using this system, the system would require a method of
maintaining the blood at 37 degrees Celsius (body temperature). In order to accomplish this, tanks were
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designed to submerge the majority of the flow systems in a heat bath. These tanks can be viewed in
Figure-3.11 (white tank) and Figure-3.10 (black tank). Heaters were built to be submersible and to allow
for temperatures up to 100 degrees Celsius. The wattage needed for the heater was calculated utilizing
Equation-3.11. This calculation gave the wattage necessary to heat the heat bath to a temperature of
37 degrees Celsius in 30 minutes. These heaters would be submerged in the fluid-filled heater tanks
and utilize a temperature controller and thermocouple to heat the tank water to 37 degrees Celsius. This
heated bath would then convect the heat to the inside of the tanks, pump, and tubing, maintaining the
temperature of blood precisely.
HW = Heater Wattage; v = Volume in Liters; Tc = Temperature Rise in Degrees Centigrade;
HW = (v ∗ 8 ∗ Tc)/3412 (3.11)
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Computational Results
4.1 Initial Conditions and Testing Criteria
A commercially available CFD package (ANSYS 15.0) was employed to mimic flow through the
pumps. A tetrahedral finite element mesh was generated through ANSYS having 2.14 million elements.
The mesh was refined by increasing the number of elements until the values calculated had minimal
variance; this is also known as obtaining grid independence. The CFD solver was set to achieve
convergence once the residual error dropped below 1 x 10-3. The computational pump models, including
the axial inducer, axial impeller, axial diffuser, axial flow straightener, centrifugal inlet volute, centrifugal
outlet volute, and centrifugal impeller domains were imported into ANSYS-CFX solver to complete the
simulations.
Flow through the pump was set to be steady and a no slip condition was applied to all stationary
surfaces. The inlet and outlet of the pump were defined as stationary boundaries. The impellers were
placed in a rotating reference frame and because of their orientation, were set to rotate in a clockwise
direction. A fluid viscosity of 0.0035 kg/m*s coupled with a fluid density of 1,050 kg/m3 was used to
define the fluid properties for the simulation.
For the axial pump, the rotational speeds ranged between 8k and 12k RPM. For the centrifugal pump,
the rotational speeds ranged between 1.75k and 2.5k RPM. Both of these pumps were tested with a
uniform mass flow rate at the inlet of the pumps. An outlet boundary surface was specified as a static
outflow pressure and as an opening boundary to capture any turbulent or irregular flow patterns exiting
the pumps.
4.1.1 Axial Pump Results
This study evaluated the pressure rise across the 15 mm (diameter) axial pump prototype for rotational
speeds of 8,000-12,000 RPM for flow rates of 4-6.5 L/min. Figure-4.1 shows pressure-flow performance
of this pump across the aforementioned speeds. Each data point represents the steady state results for an
individual CFD simulation at the previously mentioned boundary conditions. As expected, a trend of
decrease in pressure rise as a function of increasing flow rate was discovered for each rotational speed. It
was determined that the axial pump performed at its most desirable state at 9,000 RPM at 5 L/min. The
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pump speeds above 11,000 RPM generated pressure rises above 30 mmHg across the entire range of
flows. The pump speeds below 11,000 RPM encompassed the pressure-flow performance curves between
0-30 mmHg.
Figure-4.2 demonstrates the velocity streamlines for the operating point of 9,000 RPM and 5 L/min.
Per the contour plot, the streamlines are axially straight as the blood flow enters the impeller domain. In
the impeller domain, the rotational velocity of the blood is increased. As the blood leaves the impeller and
enters the diffuser, the streamlines indicate a redirection and slowing of the velocity at the pump outlet.
Figure 4.1: Computational Modeling Results of Axial Pump
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Figure 4.2: Axial Pump CFD Velocity Streamlines
Figure-4.3 illustrates the axial force-flow performance of the axial pump for rotational speeds of
7,000-12,000RPM. Expected trends were found with higher axial forces at faster rotational speeds. The
axial forces ranged from .28 to 1.4 N for the axial pump across all of the speeds. For the 9,000 RPM
speed at 5 L/min the axial pump produced .67 N of force in the axial direction.
Figure 4.3: Axial Fluid Forces on the Impeller of the Axial Flow Blood Pump
Figure-4.4 illustrates the radial force-flow performance of the axial pump for rotational speeds of
7,000-12,000 RPM. Expected trends were found with higher radial forces at higher flow rates. The radial
forces ranged from .032 to .196 N for the axial pump across all of the speeds. For the 9,000 RPM speed
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at 5 L/min the axial pump produced .11 N of force in the radial direction. The fluid power ranged from
Figure 4.4: Radial Fluid Forces on the Impeller of the Axial Flow Blood Pump
.66 to 5.54 W for the axial pump across all of the speeds. For the 9,000 RPM speed at 5 L/min the axial
pump is estimated to require an input of approximately 2.43 W of power.
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4.1.2 Centrifugal Pump Results
This study evaluated the pressure rise across the 70 mm (diameter) centrifugal pump prototype for
rotational speeds of 1,750, 2,000, 2,250, and 2,500 RPM for flow rates of 4-6.5 L/min. Figure-4.5 shows
a the performance of this pump across the aforementioned speeds. Each data point represents the steady
state results for an individual CFD simulation at the previously mentioned boundary conditions. As
expected, a trend of decrease in pressure rise as a function of increasing flow rate was discovered for each
rotational speed. It was determined that the centrifugal pump performed at design for 5 L/min at 2,250
RPM. The pump speed of 2,500 RPM generated pressure rises above 130 mmHg across the entire range
of flows. The pump speeds below 2,250 RPM produced the pressure-flow performance curves between
0-130 mmHg. Figure-4.6 illustrates the velocity streamlines of the centrifugal LVAD at the design point.
The velocity increases after passing through the volute and into the pump. After hitting the impeller, the
fluid accelerates to a higher velocity. As expected the velocity slows at the outlet, converting some of the
flow into a pressure rise. The outlet of the pump shows a desired velocity between 2 and 4 m/s.
Figure 4.5: Computational Modeling Results of Centrifugal Pump
47
Figure 4.6: Centrifugal Pump CFD Velocity Streamlines
Figure-4.7 illustrates the axial force-flow performance of the centrifugal pump for rotational speeds
of 1,750-2,500 RPM. Expected trends were found with lower axial forces at lower rotational speeds. The
axial forces ranged from .986 to 3.46 N for the centrifugal pump across all of the speeds. For the 2,250
RPM speed at 5 L/min the axial pump produced 2.52 N of force in the axial direction.
Figure 4.7: Axial Fluid Forces on the Impeller of the Axial Flow Blood Pump
Figure-4.8 illustrates the radial force-flow performance of the centrifugal pump for rotational speeds
of 1,750-2,500 RPM. Expected trends were found with higher radial forces at higher flow rates. The
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radial forces ranged from .077 to .195 N for the axial pump across all of the speeds. For the 2,250 RPM
speed at 5 L/min the axial pump produced .12 N of force in the radial direction.
Figure 4.8: Radial Fluid Forces on the Impeller of the Axial Flow Blood Pump
The fluid power ranged from .53 to 8.14 W for the axial pump across all of the speeds. For the 2,250
RPM speed at 5 L/min the axial pump is estimated to require an input of approximately 7.10 W of power.
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5
Experimental Results and Comparison to Computational Predictions
5.1 Calibration Results
5.1.1 Flow Probe Calibration Results
The flow calibration data collected (Figures-A.1, A.2, A.3) was placed into an EXCEL spreadsheet.
The flow rates and their corresponding voltages were plotted, these plots can be viewed in Figures
5.1, 5.2, 5.3. From these plots equations and confidence intervals were calculated. Equation-5.1 was
calculated from the three sets of data collected. Y represents the flow rate which will be output by the
LJstream software and X represents the voltage being provided to the software from the flow module
(Equation-5.2). The R2 correlation coefficient of these three sets of data was calculated and is shown in
Equation-5.3. The data for this plot and all of the flow sensor calibrations can be found in Table-A.5.
Y = 9.982 ∗X − 0.0519 (5.1)
(FlowRate) = 9.982 ∗ (V oltageInput)− 0.0519 (5.2)
R2 = 0.9993 (5.3)
Figure 5.1: Flow Calibration Plot and Equation-1
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Figure 5.2: Flow Calibration Plot and Equation-2
Figure 5.3: Flow Calibration Plot and Equation-3
5.1.2 Pressure Sensor Calibration Results
The pressure calibration data collected was placed into an EXCEL spreadsheet. The pressures and
their corresponding voltages were calculated and plotted (Equations-3.4, 3.5, 3.6). From these plots
shown in Figure-5.4, Figure-5.5, and Figure-5.6, an equation and confidence interval was calculated.
Equation-5.4 was calculated from an average of the three sets of pressure data collected. Y represents
the pressure differential which will be output by the LJstream software and X represents the voltage
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being provided to the software from the demodulator (Equation-5.5). The R2 correlation coefficient was
calculated and is shown in Equation-5.6. The data for these plots and all of the pressure calibrations can
be found in Tables-A.6-A.8.
Y = 15.1613 ∗X − 0.3078 (5.4)
(PressureDifferential) = 15.1613 ∗ (V oltageInput)− 0.3078 (5.5)
R2 = 0.9997 (5.6)
Figure 5.4: Pressure Calibration Plot and Equation-1
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Figure 5.5: Pressure Calibration Plot and Equation-2
Figure 5.6: Pressure Calibration Plot and Equation-3
5.1.3 Fluid Calibration Results
Once calculated, the dynamic viscosity was plotted per iteration (Figure-5.7). The dynamic viscosity
of blood, which falls between 3 and 4 cP was also plotted for comparison. The data for this plot and all
of the fluid property calibrations can be found in Figures A.1-A.4. The average viscosity for the blood
analog mixtures used was calculated to be 3.2411±0.0517 cP and the average density was calculated to
be 1.1 g/cc. The average analog fluid viscosity had a 7.4% error when compared to the target viscosity.
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Figure 5.7: Fluid Viscosity Calibration Plot
5.2 Prototype Testing Results
This section provides the results of fluid flow and pressure studies performed using both the axial
and centrifugal test-rigs shown in Figures-3.10 and 3.11. The centrifugal and axial pump configurations
were studied and tested to conclude whether their configuration and geometries would meet target design
criteria for the RVAD and LVAD.
5.2.1 Axial RVAD
In the first data collection, which included the testing of the axial pump in the axial test-rig, data was
collected for pump speeds of 6k, 7k, 8k, and 9k RPM. These results can be seen in Figure-5.8.
The RVAD generated pressure rises ranging between 15-30 mmHg and pulmonary blood flow between
4-6 L/min.76, 77 After analysis of the data this plot was generated and determined to be a sufficient coverage
of pressures for our goal ranges. However, we did not measure flow rates as high as 5 L/min in speeds
from 6-9k RPM. To cover this distribution of flow rates from 3-5 L/min we spun the impeller at higher
RPMs. Figure-5.8 shows a second run of 9k RPM to ensure repeatability of data before completing runs
of 10k, 11k, and 12k RPM.
Figure-5.8 illustrates flow rates as high as 5L/min at approximately 15 mmHg. With the combination
of data from both 6k - 9k RPM runs we observe a larger coverage of pressures and flow rates which
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encompass our target pressure and flow criteria. The 9,000 RPM runs display a (1) and a (2) which
represent the same test being completed on separate days. The 9,000 RPM run was completed again to
show repeatability of data before continuing on with data collection.
Figure 5.8: Axial Pump Hydraulic Testing: 6k-12k RPM
5.2.2 Centrifugal LVAD
In the second data collection, which included the testing of the centrifugal pump in the centrifugal
test-rig, data was collected for pump speeds of 1.25k, 1.5k, 1.75k, and 2k RPM. These results can be seen
in Figure-5.9.
The target pressure rise ranges for the LVAD is between 120 and 140 mmHg, and the flow range is
4-6 L/min.76, 77 After analysis of the data, Figure-5.9 was generated and determined to be a sufficient
coverage of pressures for our goal ranges. At speeds of 1.25k, 1.5k, and 1.75k we observed flow rates
well within our desired range of 3-5 L/min. We did not observe pressures as high as 120 mmHg (our
bottom line). To reach pressures within our desired range the centrifugal pump was spun at 1.25k and
1.5k to show that these results were repeatable. Next, the centrifugal impeller was spun at 2k RPM
which revealed the pumps ability to provide pressure of 120-140 mmHg with flow rates between 3-5 L/min.
55
Figure 5.9: Centrifugal Pump Hydraulic Testing: 1.25k-2k RPM
With both the axial and centrifugal pump providing us with pressure and flow ranges within our
desired limits we concluded prototype testing.
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5.3 Comparison of Computational Data to Experimental Data
5.3.1 Axial Pump
In determining error of the axial pump data we compared the 10,000 and 11,000 RPM computational
and experimental data sets. Figure-5.10 shows the computational and experimental data for flow and
pressure of the axial pump for these two speeds. Figures-5.11 thru 5.14 shows plots of the pressure and
flow coefficients for these four data sets. The equations from these plots are based on polynomial best-fit
trend lines. The analysis of the flow and pressure coefficients for the two speeds resulted in a %Error
of 103.27% for the 10,000 RPM data sets and 116.16% for the 11,000 RPM data sets.The methods for
determining these error values can be found in Section-3.4 and the data calculated for these analysis can
be found in Section-A.6.
Figure 5.10: Computational and Experimental Comparison of Axial Pump at Speeds of 10,000
and 11,000 RPM.
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Figure 5.11: Axial Pump Computational Flow and Pressure Coefficient Analysis at 10,000 RPM
Figure 5.12: Axial Pump Experimental Flow and Pressure Coefficient Analysis at 10,000 RPM
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Figure 5.13: Axial Pump Computational Flow and Pressure Coefficient Analysis at 11,000 RPM
Figure 5.14: Axial Pump Experimental Flow and Pressure Coefficient Analysis at 11,000 RPM
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5.3.2 Centrifugal Pump
In determining error of the centrifugal pump data we compared the 1,750 and 2,000 RPM compu-
tational and experimental data sets. Figure-5.15 shows the computational and experimental data for
flow and pressure of the centrifugal pump for these two speeds. Figures-5.16 thru 5.19 shows plots of
the pressure and flow coefficients for these four data sets. The equations from these plots are based on
polynomial best-fit trend lines. The analysis of the flow and pressure coefficients for the two speeds
resulted in a %Error of 17.10% for the 1,750 RPM data sets and 18.50% for the 2,000 RPM data sets.The
methods for determining these error values can be found in Section-3.4 and the data calculated for these
analysis can be found in Section-A.6.
Figure 5.15: Computational and Experimental Comparison of Centrifugal Pump at Speeds of
1,750 and 2,000 RPM.
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Figure 5.16: Centrifugal Pump Computational Flow and Pressure Coefficient Analysis at 1,750
RPM
Figure 5.17: Centrifugal Pump Experimental Flow and Pressure Coefficient Analysis at 1,750
RPM
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Figure 5.18: Centrifugal Pump Computational Flow and Pressure Coefficient Analysis at 2,000
RPM
Figure 5.19: Centrifugal Pump Experimental Flow and Pressure Coefficient Analysis at 2,000
RPM
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6
Discussion of Project Findings
This thesis project details the first steps in the design and development of the Dragon Heart TAH.
The research aims of the project were to: 1) Establish a hybrid combined axial and centrifugal blood
pump that could function as a TAH, whilst incorporating the latest in magnetic suspension technology; 2)
Design a test-rig and computational framework to support performance evaluation of the TAH designs; 3)
Demonstrate the abilities of the hybrid TAH to achieve target design specifications through computational
and experimental studies. All of these research aims were completed with success. This research was
successful as a hybrid TAH was produced, computationally evaluated, and experimentally tested. The
pump prototypes demonstrated performance levels meeting target design requirements. Additional effort
must be dedicated to continue to reduce the size of the TAH while not compromising performance. While
this project achieved milestones, overcoming study limitations and sources of data error are critically
important to the future success of the project.
6.1 Study Limitations
This research has limitations that must be addressed in future work and in the ongoing design and
development of this TAH. This section outlines the sources of data error and limitations of the studies
performed on both the axial and centrifugal pumps and works to outline the problems occurred, how they
were resolved, and future adjustments that can prevent and abrogate these limitations.
6.1.1 Computational Limitations
While computational modeling has grown in popularity and use in the design and development of
VADs and TAHs, it has several sources of approximations, including internal round off errors and the use
of turbulence models that only estimate the average characteristics of the physical flow phenomena. The
art of meshing requires a finite number of elements to be chosen for a particular region of the pump which
limits the values provided for calculations. By refining meshes in more active areas of the model error is
reduced, but it is never eliminated. Within the mathematical model a convergence criteria of .001 was
utilized in conjunction with the reasonable success of prior studies of similar geometries.78 A smaller
convergence criteria could have been used, but it would have required additional days of convergence time
and may not have yielded any additional accuracy in the computational predictions. The simulations were
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conducted for steady flow conditions and did not account for blade passage frequency, which could have
impacted predictions. We specified uniform flow conditions at the inlet and a static pressure condition
at the outlet, which are simplistic assumptions and again, may not portray the dynamically changing
characteristics of these boundaries.
6.1.2 Experimental Limitations
Axial Pump Experimental Limitations
During experimental testing, the axial pump (RVAD) had to be rotated using a shaft. Although we
covered this shaft with a sleeve (Figure-3.22), parts of the shaft were exposed and potentially could have
caused vortices at the trailing edges of the blades. This sleeve was not modeled on the computer CFD
simulations and therefore likely contributed to the large deviation between the data sets. The sleeve
positioned at the back of the impeller reduces the area of the outlet, compressing the fluid domain and
potentially altering the pressure values across the pump. (Chapter-4).
In the manufacturing of the axial pump, clearances between the impeller and the pump housing
components were increased to reduce the likelihood of touch-down of the blades during testing. In
addition to these clearances being larger than in the simulations, the rapid prototyping method used only
has an accuracy of ten thousandths of an inch per linear inch. This difference in geometry from the
computational model could also be cause for deviation between the data sets. The blood analog solution in
the computational testing had a fluid density of 1,050 kg/m3, while the blood analog in the experimental
testing was measured to be 1,100 kg/m3. All of the data measurements for the experimental testing
were repeatable. Thus, data repeatability was not an issue. More specifically, the axial pump showed
repeatability (Figure-6.1) with an average difference of 7.20% with a standard deviation of 6.64%.
Centrifugal Pump Experimental Limitations
While conducting bench-top testing on the centrifugal pump, large axial forces were caused by the
over performance of the pump. These forces caused the impeller to pull forward and touch-down at the
top volute (refer to Figure-3.11 for pump configuration). The impeller had to be restrained to account
for this axial thrust force and to ensure its centered location within the pump housing. Constraining the
rig, balancing, and aligning the impeller inside of the bottom volute proved to be difficult. Once proper
alignment was accomplished, an impeller was damaged by an over heating of the oil seal on the bottom
or outlet volute caused by friction between the shaft and the seal. To solve this problem a cooling drip of
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Figure 6.1: Repeated Experimental Results For Axial Pump at 9,000 RPM
ice water was applied to the shaft at the oil seal and the impeller was replaced. Manufacturing tolerances
and differences in the blood analog solution between the simulations and experiments contributed to
deviations between data sets. Figure-6.2 shows repeated results at 1,250 and 1,500 RPM. The 1,250
RPM runs showed an average difference of 5.16% with a standard deviation of 3.50%, and the 1,500
RPM runs showed with an average difference of 3.892% with a standard deviation of 6.383%
Figure 6.2: Repeated Experimental Results For Centrifugal Pump at 1,250 and 1,500 RPM
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6.1.3 Test-Rig Limitations
The test-rig had limitations that were addressed and resolved before data collection occurred. The
frequency being read from the motors’ hall sensors was extremely noisy (see (Figure-3.10 and Figure-
3.11). This noise prevented an accurate signal from being obtained. Through rigorous examination,
different components of the control system were shielded, resulting in improved hall sensor readings.
Even with the improved hall sensor readings, it was difficult to match the motor current necessary in order
to produce rotational speeds of exactly 1,500, 1,750, 8,000, and additional targeted test speeds. Future
studies will involve recording the motor frequencies during the experiment in order to more accurately
determine the actual operating speed.
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7
Conclusions and Future Work
7.1 Conclusions
The results of this thesis project demonstrate a great deal of promise associated with the new Dragon
Heart. With hundreds of the thousands of adults and children awaiting donor organs, there is a substantial
patient population who will benefit from the availability of a novel, more compact, continuous flow
TAH.24, 27
We seek to make the world’s smallest artificial heart, which can be implanted in patients of all sizes.
By doing what has never been done before and running the axial pump for the right side of the heart
through the normally void space inside of a centrifugal LVAD, the size of our TAH is reduced to be the
size of a standard VAD. We have tested each pump’s ability in these orientations and shown that their
designs and combination achieve target performance expectations. We seek to have this design completely
implantable and potentially utilize a TET system to reduce any chances for infection. To this end, we are
developing novel test-rigs and setups to accurately and precisely analyze the performance of this device
and its components. We are continuously improving and advancing the design by removing unnecessary
bulkiness and reducing its size even more through pump optimization.
If successful, this device will be able to be implanted in a larger range of people than current designs
permit and will save more lives than current designs are capable of.
7.2 The Next Step: Future Work Initiatives
The design of blood pumps or a continuous flow TAH requires a careful balance and trade-off of
geometrical characteristics that impact biomcompatibility, hydraulic performance, implantability, risk
of infection, durability, and patient selection and safety. By spinning an impeller at a higher speed the
chances of red blood cells being lysed increases, resulting in clotting and potentially death. By spinning
the pumps at lower speeds, the pressures and flow rates being targeted may not be accomplished. In
designing these sorts of pumps, it is important to take into account the hemocompatibility of the design
so that a larger range of speeds can be accomplished. By having a larger range of speeds the pump can
spin at, with minimal damage to blood, a larger range of patients to be viable recipients of the TAH is
generated.
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The pressures and flows of the pump can also be optimized through adjustment to blade geometries.
By increasing the pitch and angles of the blades, the fluid flow rate and the pressure added by the pump can
be drastically altered. The goal is to find a blade geometry and a speed it can be spun at that will provide
the target output without lysing significant amounts of red blood cells. With other blood pumps being
spun up to speeds as high as 25k RPM these two pump designs show great promise in hemocompatibility,
cardiac ouput, and cardiac pressure.79 The sizes of our pumps were prototyped to be much larger than
originally designed for, however they allowed us to accomplish a proof of concept and design. By scaling
down these pump designs, it appears as if we will be able to accomplish our target pressures and flows
with slight increases in speed. We will seek to redesign these pumps and do computational analysis on
them iteratively to decrease the size of the pumps even more.
In addition to decreasing the size of the pumps we will need to design and build a test-rig which
can accommodate both of the pumps working in series as a TAH. We will next seek to prototype the
combination of these two pumps into the compact and novel TAH configuration mentioned on Page-23,
and to test them in their final configuration. Assuming positive results, the research will need to move
into the direction of designing and building magnetically levitated motors which will spin these pumps.
The tolerances of these motors may be our biggest challenge in reducing the size of the TAH. Once a
magnetically levitated TAH has been prototyped, we will hydraulically test it in the new test-rig to ensure
both pumps provide the target criteria. Next, the TAH will need to be hemodynamically tested to ensure
hemocompatibility.
Hemocompatibility can be addressed earlier in single pump design and in the shaft driven TAH design.
Future work will seek to follow the list shown in Table-7.1 This table lists some but certainly not all of
the steps that need to be accomplished to drive this TAH into operating rooms and to begin saving lives.
In summary, the purpose of this project is to design and advance the development of a hybrid TAH.
The long-term goal is to commercialize a novel, more compact, biocompatible, energy efficient, and
effective therapeutic alternative for smaller patients with congenital heart failure. After development and
clinical testing, the Dragon Heart will be the smallest and safest TAH on the market, thus bringing more
life saving options to adults and pediatric patients (BSAs > .95 m2) in need of total cardiac support. This
thesis project performed the first design phase of the Dragon Heart with strong success and represents
the foundation by which to begin Phase II optimization and development using computational and
experimental methods.
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Table 7.1: List of future work to be completed in the design and production of The Dragon Heart
TAH.
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